CA3225427A1 - Therapeutic compounds - Google Patents
Therapeutic compounds Download PDFInfo
- Publication number
- CA3225427A1 CA3225427A1 CA3225427A CA3225427A CA3225427A1 CA 3225427 A1 CA3225427 A1 CA 3225427A1 CA 3225427 A CA3225427 A CA 3225427A CA 3225427 A CA3225427 A CA 3225427A CA 3225427 A1 CA3225427 A1 CA 3225427A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- aryl
- salt
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163213519P | 2021-06-22 | 2021-06-22 | |
| US63/213,519 | 2021-06-22 | ||
| PCT/US2022/034374 WO2022271723A1 (en) | 2021-06-22 | 2022-06-21 | Therapeutic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3225427A1 true CA3225427A1 (en) | 2022-12-29 |
Family
ID=84544904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3225427A Pending CA3225427A1 (en) | 2021-06-22 | 2022-06-21 | Therapeutic compounds |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240317749A1 (enExample) |
| EP (1) | EP4359416A4 (enExample) |
| JP (1) | JP2024524213A (enExample) |
| KR (1) | KR20240067229A (enExample) |
| CN (1) | CN118251394A (enExample) |
| AU (1) | AU2022297426A1 (enExample) |
| CA (1) | CA3225427A1 (enExample) |
| IL (1) | IL309569A (enExample) |
| MX (1) | MX2024000022A (enExample) |
| WO (1) | WO2022271723A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117815240A (zh) * | 2023-12-11 | 2024-04-05 | 兰州大学 | 一类具有二氨基吡咯并喹唑啉结构的化合物在防治奶牛乳腺炎致病菌中的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2436524T3 (es) * | 2003-05-22 | 2014-01-02 | Nerviano Medical Sciences S.R.L. | Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas |
| US8673929B2 (en) * | 2006-07-20 | 2014-03-18 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections |
| US20090227575A1 (en) * | 2008-03-04 | 2009-09-10 | Wyeth | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS |
| BR112013008527A2 (pt) * | 2010-12-17 | 2016-07-12 | Nerviano Medical Sciences Srl | derivados de pirazolo-quinazolina substituídos como inibidores de cinase |
| US12428423B2 (en) * | 2017-04-01 | 2025-09-30 | Shengke Pharmaceuticals (Jiangsu) Ltd. | 1H-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor |
| US11077109B2 (en) * | 2017-08-01 | 2021-08-03 | The Trustees Of Princeton University | Compounds having antibacterial activity and methods of use |
| KR102464677B1 (ko) * | 2017-08-11 | 2022-11-10 | 셍커 파마슈티컬스 (지앙수) 엘티디. | 단백질 인산화효소 억제제로 작용하는 1h-피라졸로[4,3-h]퀴나졸린 화합물 |
| CN119455003A (zh) * | 2019-02-12 | 2025-02-18 | Ambrx公司 | 包含抗体-tlr激动剂缀合物的组合物、方法和用途 |
| WO2022040596A1 (en) * | 2020-08-20 | 2022-02-24 | Ambrx, Inc. | Antibody-tlr agonist conjugates, methods and uses thereof |
| EP4204093A1 (en) * | 2020-08-27 | 2023-07-05 | Shengke Pharmaceuticals (Jiangsu) Ltd. | 1h-imidazo [4,5-h] quinazoline compound as novel selective flt3 inhibitors |
-
2022
- 2022-06-21 IL IL309569A patent/IL309569A/en unknown
- 2022-06-21 WO PCT/US2022/034374 patent/WO2022271723A1/en not_active Ceased
- 2022-06-21 US US18/572,411 patent/US20240317749A1/en active Pending
- 2022-06-21 EP EP22829168.8A patent/EP4359416A4/en active Pending
- 2022-06-21 AU AU2022297426A patent/AU2022297426A1/en active Pending
- 2022-06-21 CN CN202280057092.XA patent/CN118251394A/zh active Pending
- 2022-06-21 KR KR1020247002091A patent/KR20240067229A/ko active Pending
- 2022-06-21 CA CA3225427A patent/CA3225427A1/en active Pending
- 2022-06-21 JP JP2023578915A patent/JP2024524213A/ja active Pending
- 2022-06-21 MX MX2024000022A patent/MX2024000022A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022271723A1 (en) | 2022-12-29 |
| EP4359416A1 (en) | 2024-05-01 |
| AU2022297426A1 (en) | 2024-02-01 |
| MX2024000022A (es) | 2024-03-15 |
| JP2024524213A (ja) | 2024-07-05 |
| US20240317749A1 (en) | 2024-09-26 |
| IL309569A (en) | 2024-02-01 |
| CN118251394A (zh) | 2024-06-25 |
| KR20240067229A (ko) | 2024-05-16 |
| EP4359416A4 (en) | 2025-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11845742B2 (en) | Therapeutic compounds and methods to treat infection | |
| ES2660973T3 (es) | Compuesto de quinolona | |
| CA2901502C (en) | Amide compounds for the treatment of hiv | |
| US9926261B2 (en) | Bacterial efflux pump inhibitors | |
| US9950993B2 (en) | Bacterial efflux pump inhibitors | |
| US11458121B2 (en) | Therapeutic compounds and methods to treat infection | |
| WO2018218192A1 (en) | Bacterial efflux pump inhibitors | |
| US10556854B2 (en) | Bacterial efflux pump inhibitors | |
| JP2012532187A (ja) | イミダゾ［４，５−ｃ］キノリン誘導体ならびに腫瘍および／または炎症の治療におけるそれらの使用 | |
| WO2018165614A1 (en) | Bacterial efflux pump inhibitors | |
| US10836706B2 (en) | Bacterial efflux pump inhibitors | |
| WO2018165612A1 (en) | Bacterial efflux pump inhibitors | |
| US20190031624A1 (en) | Therapeutic compounds and methods to treat infection | |
| JP6411355B2 (ja) | 抗菌剤 | |
| JPH06506443A (ja) | アザ二環式およびアザ三環式誘導体、その製法および中間体ならびに該化合物含有の医薬組成物 | |
| AU2016353348A1 (en) | Heterocyclic compounds for the treatment of disease | |
| KR20150007352A (ko) | Kat ii 억제제로서 삼환 화합물 | |
| KR20190064625A (ko) | Ror 감마 조정제로서의 헤테로시클릭 술폰 | |
| WO2022271723A1 (en) | Therapeutic compounds | |
| EP3434669A1 (en) | Intermediate compounds utilizable in synthesis of (-) huperzine and process for obtain one of these intermediate compounds | |
| WO2021243273A1 (en) | Bacterial efflux pump inhibitors | |
| AU2024327693A1 (en) | Bacterial efflux pump inhibitors | |
| HK40112157A (en) | The pharmaceutical use of enpp1 inhibitors | |
| HK1215031B (en) | Antimicrobial agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250707 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250707 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251224 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260602 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260602 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260619 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260619 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260619 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260723 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260723 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260723 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260723 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260723 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260723 |